Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: A case report

Oncologist

Volumn 15, Issue 9, 2010, Pages 965-968

  Ong, Sin Jen ^a   Teo, Marissa ^a   Lim, Kiat Hon ^b   Choo, Su Pin ^a   Toh, Han Chong ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Gastroesophageal carcinoma; mTOR; Rapamycin; Thalidomide

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; I KAPPA B KINASE BETA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; THALIDOMIDE; VASCULOTROPIN RECEPTOR;

ADRENAL METASTASIS; ADULT; ALTERNATIVE MEDICINE; ANEMIA; ARGON PLASMA COAGULATION; ARTICLE; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL SURGERY; HEMATEMESIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TREATMENT REFUSAL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; MALE; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIROLIMUS; STOMACH NEOPLASMS; THALIDOMIDE; TOR SERINE-THREONINE KINASES;

EID: 77957771800     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0118     Document Type: Article

References (14)

1. Yu GZ, Wang JJ, Chen Y et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009;15:1821-1829.
2. Yen CJ, Izzo JG, Lee DF et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's- associated esophageal adenocarcinoma. Cancer Res 2008;68:2632-2640.
3. Boone J, Ten Kate FJW, Offerhaus GJA et al. mTOR in squamous cell carcinoma of the oesophagus: A potential target for molecular therapy? J Clin Pathol 2008;61:909-913.
4. Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007;120:1803-1810.
5. Doi T, Muro K, Boku N et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28:1904-1910.
6. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sc i U S A 1994;91:4082-4085.
7. Kotoh T, Dhar DK, Masunaga R et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-544.
8. Khan ZH, Simpson EJ, Cole AT et al. Oesophageal cancer and cachexia: The effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17:677-682.
9. Huynh H, Chow PK, Palanisamy N et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 2008;49:52-60.
10. Raje N, Kumar S, Hideshima T et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104:4188-4193.
11. Lambert K, Ward J. The use of thalidomide in the management of bleeding from a gastric cancer. Palliat Med 2009;23:473-475.
12. Lang SA, Hackl C, Moser C et al. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF- IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta 2010;1803:435-442.
13. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)- positive advanced gastric cancer (GC). J Clin Oncol 2009;27(18 suppl): LBA4509.
14. Miller TW, Forbes JT, Shah C et al. Inhibition of mammalian target of rapa- mycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009;15:7266-7276.